KAI1基因在非小细胞肺癌中的表达及意义  

Expression of KAI1 Gene in Non-small Cell Lung Cancer and Its Clinical Significance

作　　者：杨琴[1] 陈红雷[2] 陈德基[2] 张兆祥[1] 石新兰[1] 刘铭球[2] 

机构地区：[1]三峡大学医学院病理教研室,湖北宜昌433000 [2]武汉大学医学院病理教研室

出　　处：《肿瘤防治研究》2009年第6期490-493,共4页Cancer Research on Prevention and Treatment

基　　金：国家自然科学基金资助项目(39870305)

摘　　要：目的探讨肿瘤转移抑制基因KAI1基因在非小细胞肺癌组织中的表达及其与患者临床病理指标的关系。方法采用RT-PCR和Western blot法,检测48例肺癌患者手术切除的新鲜肺癌组织标本和20例同期手术切除的肺部良性病变周围正常组织中KAI1mRNA、KAI1/CD82,并结合患者的临床病理资料对其结果进行统计分析。结果肺癌组织和肺部良性病变组织中KAI1mRNA的阳性率分别为52%和90%,KAI1/CD82蛋白的阳性率分别为48%和85%,肺癌组KAI1mRNA及KAI1/CD82蛋白表达均低于肺部良性病变组(P<0.01);KAI1mRNA、KAI1/CD82表达水平与肺癌患者的临床分期、组织分化程度、淋巴结转移有关(P<0.05),其中KAI1/CD82表达与淋巴结转移状况密切相关(P<0.01),肺癌组织中KAI1mRNA与KAI1/CD82表达有相关性(P<0.01)。结论KAI1基因的低表达可能与非小细胞肺癌的发生、发展和转移有关;其下调的机制可能主要发生在转录水平;KAI1基因的表达可作为一项评估肺癌患者转移潜能的指标。Objective To investigate the expression of KAI1, as a suppressor of metastasis, in the tissues of NSCLC and its relationship with the clinicopathological indexes. Methods The expressions of KAI1/ CD82 protein were detected with Western blot in 48 cases of NSCLC from patients with lung cancer and benign lung tissue of patients with benign lung disease undergoing surgery in our hospital. The RT-PCR method was also used to assess KAI1 mRNA in the same tissue samples, and the results were statistically analyzed. Results The positive rates of KAI1 mRNA in NSCLC and benign lung tissues were 52% ,90% respectively;the positive rates of KAI1/CD82 in NSCLC and benign lung tissues were 48%,85 % respectively（P〈0. 01 ）. The expression level of KAIlrnRNA and KAI1/CD82 protein in lung cancer were lower than those in benign lung tissue（P〈0. 01）. The expression level of KAI1/CD82 were correlated with tumor stage,grade of tumor differentiation and metastasis status （P〈0. 05）, among which the metastasis status in particular（P〈0. 01 ）. The expression of KAI1/CD82 had relations with its mRNA（P〈0. 01）. Conclusion The down-regulation of KAI1 may be correlated with carcinogenesis, development and metastasis in NSCLC. Its reduction may be mainly at transcriptional level, and it could be used as a marker for predicting the potential metastasis and prognosis of patients with NSCLC.

关 键 词：KAI1基因 非小细胞肺癌 逆转录-聚合酶链反应 蛋白质免疫印记分析 

分 类 号：R734.2[医药卫生—肿瘤]